Tripos Faces Delisting From Nasdaq for Low Share Price, Market Cap

Jan 11, 2007

NEW YORK (GenomeWeb News) — Tripos today said it is in jeopardy of being delisted from the Nasdaq exchange for not maintaining the minimum market cap and minimum share bid price for 30 consecutive days.

The company said it has 90 days to regain market-cap compliance and 180 days to regain share-price compliance or it will be delisted from the market.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marine Mammal Gene Loss

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

Cell Count

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

Varied Opinions

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

This Week in PNAS

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.

Featured White Papers

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Probe Design and In Vitro Validation Quick Start Guide

Aug

20

Featured Webinar

GenomeWeb/ABRF 2018 Webinar Series: Advances in Single-Cell RNA-Seq: Novel Technologies, Practical Applications

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.

Aug

27

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Main menu